Margriet Kwint

Outcome of treatment of synchronous oligometastases 57 3 Type Systemic Therapy None 16 (17.6%) Daily lowdose Cisplatin (Concurrent) 6 (6.6%) Cisplatin-Etoposide (Concurrent) 2 (2.2%) Cisplatin-Pemetrexed (Concurrent) 1 (1.1%) Cisplatin-Pemetrexed 26(28.6%) Cisplatin-Gemcitabine 12 (13.2%) Cisplatin-Etoposide 2 (2.2%) Cisplatin-Pemtrexed+ Pemetrexed maintenance 2 (2.2%) Cisplatin/Carboplatin-Gemcitabine 2 (2.2%) Carboplatin-Gemcitabine 7 (7.7%) Carboplatin-Pemetrexed 9 (9.9%) Tarceva 2 (2.2%) Gefitinib 4 (4.4%) Table 3: treatment characteristics of the metastases. RT= Radiotherapy, RFA = Radio Frequency Ablation Treatment of the metastases N (%) Stereotactic Radiotherapy 44 (48.4%) Brain 24 Adrenal gland 10 Bone 8 Brain & bone 1 Brain & adrenal gland 1 Conventional radiotherapy within thoracic RT-field 20 (22.0%) Bone 12 Lymph node 4 Soft Tissue 1 Pulmonary 1 Thyroid gland 1 Bone & Pleura 1 Conventional radiotherapy 7 (7.7%) Bone 3 Lymph node 2 Liver 1 breast 1 Systemic therapy only 6 (6.6%) brain 4 Adrenal gland 1 Liver & bone 1 Surgery and radiotherapy 6 (6.6%) Brain 4